Moreadith Randall 4

What Happened

• Moreadith Randall, Chief Scientific Officer of Serina Therapeutics (SER), received a grant of 85,558 derivative shares on 2026-05-21. The Form 4 reports an acquisition price of $0.00 (derivative award/option), so the filing lists $0 as the reported value. This was an equity comp award to an executive rather than an open-market purchase or sale.

Key Details

• Transaction date: 2026-05-21; Form 4 filed: 2026-05-26 (5 days after the transaction — outside the usual 2-business-day window for timely Form 4 filings).
• Transaction type/code: Award/Grant (A); reported as a derivative instrument (option).
• Shares/amount: 85,558 shares granted; reported acquisition price $0.00.
• Shares owned after the transaction: Not specified in the provided filing.
• Footnote: Vesting schedule — 12/48ths of the option vests 12 months after the Vesting Commencement Date, then 1/48th vests each month thereafter until fully vested (i.e., a standard 4-year vesting with a 1-year cliff).
• No indication in the filing that shares were immediately sold (no cashless exercise); this appears to be a standard compensation grant.

Context

• This is a compensation grant (an option/derivative award) to an executive; such awards are common for retention and alignment with shareholders and do not by themselves indicate a buy or sell signal. The reported $0.00 acquisition price reflects the accounting/reporting of the grant, not its market value. The delayed filing may be of interest to compliance-minded investors, as Form 4s are generally expected within two business days of the transaction.